← Back to Analyst Consensus 
SNTI Buy
Senti Biosciences Holdings, Inc.
Current Price —
Implied Upside —
Analysts 8
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (13 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| May 15, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 30, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Dec 9, 2025 | Chardan Capital | maintain | Buy → Buy | $13 | 47% |
| Nov 21, 2025 | Leerink Partners | initiate | — → Outperform | $6 | 51% |
| Oct 14, 2025 | HC Wainwright & Co. | initiate | — → Buy | $12 | 44% |
| Aug 8, 2025 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Jun 12, 2025 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Jun 6, 2025 | Laidlaw & Co. | initiate | — → Buy | $15 | 18% |
| May 2, 2025 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Dec 4, 2024 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Dec 2, 2024 | Chardan Capital | maintain | Buy → Buy | $10 | 47% |
| Aug 15, 2023 | Chardan Capital | reiterate | Buy → Buy | $6 | 47% |
| May 11, 2023 | Chardan Capital | maintain | Buy → Buy | $6 | 47% |
| Mar 24, 2023 | Morgan Stanley | maintain | — → Equal-Weight | $2 | 54% |
| Mar 23, 2023 | Chardan Capital | maintain | — → Buy | $7 | 47% |
| Jan 30, 2023 | Chardan Capital | maintain | — → Buy | $8 | 47% |
| Jan 27, 2023 | Morgan Stanley | maintain | — → Equal-Weight | $3 | 54% |
| Dec 16, 2022 | JP Morgan | initiate | — → Neutral | $0 | 55% |
| Oct 7, 2022 | Morgan Stanley | initiate | — → Equal-Weight | $7.5 | 54% |
| Sep 29, 2022 | B of A Securities | initiate | — → Buy | $7 | 53% |
| Sep 23, 2022 | Chardan Capital | initiate | — → Buy | $12 | 47% |
Price Target Trend
Mar 27, 2026 Oct 26, 2026
EPS Estimates
+1q —
0y —
0q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days